Robert Wild to Risk Assessment
This is a "connection" page, showing publications Robert Wild has written about Risk Assessment.
Connection Strength
0.558
-
Insights from the Women's Health Initiative: individualizing risk assessment for hormone therapy decisions. Semin Reprod Med. 2014 Nov; 32(6):433-7.
Score: 0.100
-
Osteoporosis: therapeutic guidelines. Guidelines for practice management of osteoporosis. Clin Obstet Gynecol. 2013 Dec; 56(4):694-702.
Score: 0.095
-
Planning a clinical trial. J Clin Lipidol. 2012 Nov-Dec; 6(6):484-95.
Score: 0.087
-
Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010 May; 95(5):2038-49.
Score: 0.073
-
Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint. Am J Obstet Gynecol. 2008 Jan; 198(1):4-6.
Score: 0.063
-
A personalized medicine approach to ovulation induction/ovarian stimulation: development of a predictive model and online calculator from level-I evidence. Fertil Steril. 2022 02; 117(2):408-418.
Score: 0.042
-
Lipoprotein(a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative. J Vasc Surg. 2021 04; 73(4):1245-1252.e3.
Score: 0.038
-
Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur Heart J. 2019 09 07; 40(34):2849-2855.
Score: 0.035
-
National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014 Sep-Oct; 8(5):473-88.
Score: 0.025